What is Sitryx?
Sitryx is a biopharmaceutical firm dedicated to modulating cell metabolism for novel treatments in immuno-inflammation and immuno-oncology. Founded by six eminent researchers in immunology and metabolism, the company leverages deep scientific expertise and a robust pipeline of drug discovery projects. Its foundational science is built upon breakthroughs in understanding the energetic status of immune cells and broader immunological principles. The company's strategic collaborations and investment rounds indicate a strong trajectory in advancing its therapeutic candidates.
How much funding has Sitryx raised?
Sitryx has raised a total of $69M across 2 funding rounds:
Series A
$30M
Other Financing Round
$39M
Series A (2018): $30M, investors not publicly disclosed
Other Financing Round (2023): $39M led by Oxford Sciences Enterprises, Sofinnova Partners, and Eli Lilly
Key Investors in Sitryx
Oxford Sciences Enterprises
Oxford Science Enterprises is an investment company with a unique partnership with the University of Oxford, focusing on building transformational businesses.
Sofinnova Partners
Sofinnova Partners is a leading European venture capital firm specializing in life sciences, actively building companies from seed to later stages.
Eli Lilly
Eli Lilly and Company is a global biopharmaceutical firm focused on the discovery, development, and commercialization of prescription medicines across various therapeutic areas.
What's next for Sitryx?
With the recent major strategic investment, Sitryx is poised to accelerate its drug discovery and development programs. The company's focus on regulating cell metabolism for conditions in immuno-inflammation and immuno-oncology suggests a strategic expansion into complex disease areas. Future endeavors will likely involve advancing its pipeline projects through preclinical and clinical stages, potentially forging further strategic alliances, and leveraging its scientific foundation to achieve key development milestones.
See full Sitryx company page
